TABLE 1.
Relationship between TK1 expression and clinicopathological features in patients with PCa.
| Characteristics | Low expression of TK1 | High expression of TK1 | p Value |
|---|---|---|---|
| N | 249 | 250 | |
| Age, n (%) | 0.022 | ||
| ≤60 | 125 (25.1%) | 99 (19.8%) | |
| >60 | 124 (24.8%) | 151 (30.3%) | |
| Race, n (%) | 0.781 | ||
| Asian | 5 (1%) | 7 (1.4%) | |
| Black or African American | 30 (6.2%) | 27 (5.6%) | |
| White | 207 (42.8%) | 208 (43%) | |
| T stage, n (%) | <0.001 | ||
| T2 | 118 (24%) | 71 (14.4%) | |
| T3 | 124 (25.2%) | 168 (34.1%) | |
| T4 | 3 (0.6%) | 8 (1.6%) | |
| N stage, n (%) | 0.007 | ||
| N0 | 180 (42.3%) | 167 (39.2%) | |
| N1 | 27 (6.3%) | 52 (12.2%) | |
| M stage, n (%) | 1.000 | ||
| M0 | 225 (49.1%) | 230 (50.2%) | |
| M1 | 1 (0.2%) | 2 (0.4%) | |
| PSA (ng/ml), n (%) | 0.158 | ||
| <4 | 220 (49.8%) | 195 (44.1%) | |
| ≥4 | 10 (2.3%) | 17 (3.8%) | |
| Gleason score, n (%) | <0.001 | ||
| 6 | 33 (6.6%) | 13 (2.6%) | |
| 7 | 146 (29.3%) | 101 (20.2%) | |
| 8 | 30 (6%) | 34 (6.8%) | |
| 9 | 39 (7.8%) | 99 (19.8%) | |
| 10 | 1 (0.2%) | 3 (0.6%) | |
| Residual tumor, n (%) | 0.003 | ||
| R0 | 173 (37%) | 142 (30.3%) | |
| R1 | 58 (12.4%) | 90 (19.2%) | |
| R2 | 3 (0.6%) | 2 (0.4%) | |
| Age, mean ± SD | 60.53 ± 7.11 | 61.52 ± 6.49 | 0.104 |